Association of Serum Sclerostin with Bone Sclerostin in Chronic Kidney Disease is Lost in Glucocorticoid Treated Patients
Open Access
- 7 November 2018
- journal article
- research article
- Published by Springer Nature in Calcified Tissue International
- Vol. 104 (2) , 214-223
Abstract
The osteocytic protein sclerostin inhibits bone turnover. Serum sclerostin rises early in chronic kidney disease (CKD), but if this reflects osteocyte sclerostin production is unclear, since sclerostin is also expressed in extra-skeletal tissue. Glucocorticoid treatment impacts on serum sclerostin, but the effect on the association between serum and bone sclerostin is unknown. We sought to determine whether serum sclerostin reflects bone sclerostin in different CKD stages and how this association is influenced by glucocorticoid treatment. In a cross-sectional analysis, we investigated serum sclerostin, bone sclerostin by immunohistochemistry, and bone histomorphometry in iliac crest bone biopsies from 43 patients with CKD 3–5D, including 14 dialysis patients and 22 transplanted patients (18 kidney, 4 other). Thirty-one patients were on glucocorticoid treatment at time of biopsy. Patients with low bone turnover (bone formation rate < 97 µm²/mm²/day; N = 13) had higher median serum sclerostin levels (224.7 vs. 141.7 pg/ml; P = 0.004) and higher bone sclerostin, expressed as sclerostin positive osteocytes per bone area (12.1 vs. 5.0 Scl+ osteocytes/B.Ar; P = 0.008), than patients with non-low bone turnover (N = 28). In linear regression analyses, correcting for age, gender, dialysis status and PTH, serum sclerostin was only associated with bone sclerostin in patients not treated with glucocorticoids (r2 = 0.6, P = 0.018). For the first time, we describe that female CKD patients have higher median bone sclerostin than males (11.7 vs. 5.7 Scl+ osteocytes/B.Ar, P = 0.046), despite similar serum sclerostin levels and bone histo-morphometric parameters. We conclude that glucocorticoid treatment appears to disrupt the association of serum sclerostin with bone sclerostin in CKD.Keywords
Funding Information
- Hjärt-Lungfonden (20160384)
- Stockholms Läns Landsting (20150117)
This publication has 48 references indexed in Scilit:
- Sclerostin deficiency modifies the development of CKD-MBD in miceBone, 2018
- Circulating levels of sclerostin but not DKK1 associate with laboratory parameters of CKD-MBDPLOS ONE, 2017
- The vulnerable patient with chronic kidney diseaseNephrology Dialysis Transplantation, 2015
- From skeletal to cardiovascular disease in 12 steps—the evolution of sclerostin as a major player in CKD-MBDPediatric Nephrology, 2015
- Adynamic Bone Disease: From Bone to Vessels in Chronic Kidney DiseaseSeminars in Nephrology, 2014
- Chronic Kidney Disease: A Clinical Model of Premature AgingAmerican Journal of Kidney Diseases, 2013
- ForewordKidney International, 2009
- Targeted Deletion of the Sclerostin Gene in Mice Results in Increased Bone Formation and Bone StrengthJournal of Bone and Mineral Research, 2008
- Control of bone formation by osteocytes? lessons from the rare skeletal disorders sclerosteosis and van Buchem diseaseBoneKEy Reports, 2005
- Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormoneAmerican Journal of Kidney Diseases, 2000